Why Is Moderna Stock Trading Higher On Tuesday?

1. Moderna's stock rose 5.75% to $36.02 amid strong trading volume. 2. U.S. HHS is funding mRNA-based pandemic influenza vaccine development. 3. A $590 million award supports late-stage vaccine development and additional studies. 4. Moderna advances mRNA-1018 to Phase 3 after promising Phase 1/2 results. 5. Focus on respiratory viruses and rare diseases as part of Moderna's 2025 portfolio.